Switch theme
Sign up to access all valuation multiples
Harvard Apparatus Regenerative Technology Inc is a clinical-stage biotechnology company developing regenerative-medicine treatments for disorders of the gastrointestinal system and the airway resulting from cancer, trauma, or birth defects. The company's technology is based on its proprietary cell-therapy platform that uses a patient’s stem cells to regenerate and restore function to damaged organs.
2012
8
Last FY Revenue $0.4M
Last FY EBITDA -$7.5M
$24.8M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Harvard Apparatus achieved revenue of $0.4M and an EBITDA of -$7.5M.
Harvard Apparatus expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Harvard Apparatus valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $0.4M | XXX | XXX | XXX |
| Gross Profit | XXX | $0.2M | XXX | XXX | XXX |
| Gross Margin | XXX | 37% | XXX | XXX | XXX |
| EBITDA | XXX | -$7.5M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -1750% | XXX | XXX | XXX |
| EBIT | XXX | -$7.7M | XXX | XXX | XXX |
| EBIT Margin | XXX | -1797% | XXX | XXX | XXX |
| Net Profit | XXX | -$7.7M | XXX | XXX | XXX |
| Net Margin | XXX | -1798% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Harvard Apparatus's stock price is $2.
Harvard Apparatus has current market cap of $26.3M, and EV of $24.8M.
See Harvard Apparatus trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $24.8M | $26.3M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Harvard Apparatus has market cap of $26.3M and EV of $24.8M.
Harvard Apparatus's trades at 57.7x EV/Revenue multiple, and -3.3x EV/EBITDA.
Equity research analysts estimate Harvard Apparatus's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Harvard Apparatus's P/E ratio is not available.
See valuation multiples for Harvard Apparatus and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $26.3M | XXX | $26.3M | XXX | XXX | XXX |
| EV (current) | $24.8M | XXX | $24.8M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 57.7x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -3.3x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -3.2x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -3.4x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -5.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialHarvard Apparatus's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $1.0M for the same period.
Harvard Apparatus's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Harvard Apparatus's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Harvard Apparatus and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -1750% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 129% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 537% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 1834% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Lineage Cell Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Arovella Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Aroa Biosurgery | XXX | XXX | XXX | XXX | XXX | XXX |
| Cynata Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Mesoblast | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Harvard Apparatus acquired XXX companies to date.
Last acquisition by Harvard Apparatus was XXXXXXXX, XXXXX XXXXX XXXXXX . Harvard Apparatus acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Harvard Apparatus founded? | Harvard Apparatus was founded in 2012. |
| Where is Harvard Apparatus headquartered? | Harvard Apparatus is headquartered in United States of America. |
| How many employees does Harvard Apparatus have? | As of today, Harvard Apparatus has 8 employees. |
| Is Harvard Apparatus publicy listed? | Yes, Harvard Apparatus is a public company listed on PINX. |
| What is the stock symbol of Harvard Apparatus? | Harvard Apparatus trades under HRGN ticker. |
| When did Harvard Apparatus go public? | Harvard Apparatus went public in 2013. |
| Who are competitors of Harvard Apparatus? | Similar companies to Harvard Apparatus include e.g. Lineage Cell Therapeutics, Arovella Therapeutics, Aroa Biosurgery, Cynata Therapeutics. |
| What is the current market cap of Harvard Apparatus? | Harvard Apparatus's current market cap is $26.3M |
| Is Harvard Apparatus profitable? | Yes, Harvard Apparatus is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
